New research zeroes in on a unique group of immune cells that could transform how we treat—and possibly prevent—severe food ...

Sonoma Biotherapeutics on Wednesday announced that it received a $45 million payment from Regeneron Pharmaceuticals for meeting a significant milestone in its efforts to research, develop and comm ...

A new study has revealed that a special group of cells in the intestines tamp down the immune responses caused by exposure to food proteins. Called 'tolerogenic dendritic cells,' these cells enable ...

Littman is a co-founder of Vendanta Biosciences and ImmunAI, and serves on the advisory boards of IMIDomics, Sonoma Biotherapeutics, NILO Therapeutics, and Evommune, and on the board of directors ...